<DOC>
	<DOCNO>NCT02288377</DOCNO>
	<brief_summary>This European , prospective , multicentre , double-blind randomise study evaluate effect lanreotide ( 120 mg every 28 day disease progression ) versus placebo patient metastatic/locally advanced , non-resectable , duodeno-pancreatic neuroendocrine tumour .</brief_summary>
	<brief_title>A Study Evaluating Lanreotide Maintenance Therapy Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors ( REMINET )</brief_title>
	<detailed_description>This European , prospective , multicentre , double-blind randomise study evaluate lanreotide ( 120 mg every 28 day disease progression ) versus placebo patient metastatic/locally advanced , non-resectable , duodeno-pancreatic neuroendocrine tumour . Depending phase II result , study may continue phase III . The treatment follow-up patient phase II phase III . After first-line treatment , patient randomly assign 1:1 ratio receive either lanreotide placebo . The study treatment initiate within 6 week follow confirmation date stable disease objective response . Treatment period : For patient , investigational product ( lanreotide placebo ) provide accord double-blind procedure disease progression toxicity , accordance protocol . The estimated average treatment duration patient 12 month . Follow-up period : To evaluate overall survival , patient phase II minimum follow-up period 12 month ; study continue phase III , patient maximum follow-up period 10 year . Phase III patient minimum follow-up period 5 year .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Metastatic ( synchronous metachronous ) locally advanced , nonresectable , welldifferentiated duodenopancreatic neuroendocrine tumour , grade 1 2 ( WHO 2010 classification ; Ki67 ≤ 20 % ) Progressive firstline treatment Histologically confirm ( either primary tumour metastasis ) Pathological diagnosis validate NET consult pathologist Documented stable disease objective response firstline treatment , within 4 week ( 28 day ) prior randomisation The firstline treatment consist either chemotherapy biotherapy ( everolimus sunitinib ) refer TNCD ENETS guideline . Treatment must administer 3 6 month chemotherapy 6 month biotherapy Nonfunctional tumour gastrinoma control PPIs Age &gt; = 18 year WHO 0 , 1 2 Effective contraception male female patient childbearing age , define : oral contraceptive , intrauterine device , barrier contraceptive method along spermicide gel , surgical sterilisation . Female patient use contraception throughout treatment period 6 month last treatment administration . Male patient use contraception throughout treatment period 3 month last treatment administration . Signed informed consent prior initiation studyspecific procedure treatment . History haematological malignancy cancer , except treat 5 year consider cure , carcinoma situ cervix treat skin cancer ( exclude melanoma ) Poorly differentiate neuroendocrine carcinoma NET grade 3 ENETS ( Ki67 &gt; 20 % ) If primary resect , bone metastasis exclusively Pretreatment somatostatin longacting analogue Total bilirubin ≥ 60 µmol/L Uncontrolled diabetes Contraindication product use study component Tumour arise context genetic disease Pregnancy lactation Patients unable undergo medical followup due geographical , social , psychological legal reason Concomitant participation another clinical trial investigate treatment treatment phase within 30 day prior start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lanreotide</keyword>
	<keyword>Duodeno-pancreatic neuroendocrine tumour</keyword>
	<keyword>Maintenance treatment</keyword>
</DOC>